Insights

Do you want your startup to expand and become a major player in your industry? If so, you will most likely need to seek capital from outside investors to help you build infrastructure and fulfill orders.

There were two significant developments recently at the Federal Trade Commission (FTC) in its enforcement of the Robinson-Patman Act (RPA), a statute that broadly prohibits sellers from engaging in price discrimination that harms competition. First, the Commission settled a litigation against Southern Glazer’s that was initially brought during the Biden administration, and second, the Commission also announced the resolution of an investigation into price discrimination by Gildan Activewear and S&S holdings in the wholesale T-shirt distribution industry. These developments signal a more measured approach to the RPA than in the prior administration but are nonetheless a reminder to companies that the RPA is alive and well and remains an important tool for enforcers and plaintiffs to address price discrimination. Companies that sell to retailers or operate in distribution channels should consider periodic reviews of their pricing structures and compliance programs to ensure compliance with the RPA. 

Senator Maria Cantwell (D-Wash), the ranking member of the Senate Committee on Commerce, Science, and Transportation, recently outlined a comprehensive artificial intelligence (AI) governance framework designed to drive legislative and executive actions. The framework is built on six principles and is being introduced at a time when federal AI legislation is actively being debated. While the framework is a proposal, it reflects priorities that have bipartisan resonance and signals where lawmakers are likely to focus. For health insurance payors, several elements of the framework are directly relevant to existing and planned AI deployments, particularly in utilization management, claims processing, and member-facing services.

Following the Board’s November 8, 2024, decision reversing the Examiner’s OTDP rejections of claims 1-18 of U.S. Application No. 17/135,529 (the ’529 Application), the patent application at issue in Ex parte Baurin, the Examiner filed a request for rehearing. On March 5, 2026, USPTO Director Squires convened the ARP and granted sua sponte rehearing. Eleven amicus briefs were entered into the record on April 1, 2026. 

At a glance: A New Mexico jury found Meta liable for nearly 44 million deceptive trade practice violations based on misleading privacy and platform-safety statements—showing that public-facing privacy claims can create significant consumer-protection exposure.

At a glance: Governor Gavin Newsom signed SB 690, amending CIPA to restrict private plaintiffs from bringing “pen register” and “trap and trace” claims arising from web-based conduct. The amendment is meant to reduce the wave of private CIPA litigation targeting website tracking technology. However, businesses remain exposed to several major types of claims and enforcement mechanisms under CIPA and related statutes and should audit their tracking technologies, consent mechanisms, and litigation posture accordingly.

Last week during the National Advertising Division 2026 Annual Conference, the Federal Trade Commission (FTC) provided insights on its enforcement priorities, and the National Advertising Division (NAD) provided updates on recent cases and procedural updates. 

On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for the two agencies to share non-public information concerning FDA-regulated products and the companies and individuals engaged in their manufacture, distribution, and sale. The MOU was signed by SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantas. It takes immediate effect and runs for three years, subject to renewal, modification, or termination. In a press release, Chairman Atkins described FDA-related disclosures by public companies as having “a significant impact on our markets” and identified the FDA as “a valuable partner in our efforts to administer and enforce applicable disclosure requirements under the federal securities laws.” Acting Commissioner Diamantas framed the MOU as protecting “both the patients who rely on FDA-regulated products, and the public trust that drives health care innovation.”

On September 11, 2026, the OCC, FDIC, Federal Reserve, and NCUA proposed to replace the 2023 Interagency Guidance on Third-Party Relationships with a shorter, principles-based document.1 Two companion releases complete the package: a final interagency statement on the supervision of the use of core service providers by community banks, effective on issuance,2 and a proposed Federal Reserve guide for traditional community banks (the Community Bank Guide).3 Comments are due November 16, 2026.4

The rapid emergence of AI/ML tools in drug discovery, from target identification to generative molecular design, lead optimization, and repurposing, has transformed how life sciences companies build some of their most valuable assets. As AI/ML tools take on an increasingly significant role in the drug discovery process, companies face a set of largely unresolved IP challenges that require careful planning and proactive governance.  

The FTC notched a recent win in federal court, securing a permanent injunction halting the combination of the two dominant brands of construction adhesives, Loctite and Liquid Nails.  In the recently unsealed decision, the court focused on the extensive head-to-head competition between the parties and the importance of brand equity in siding with the FTC, offering important lessons for merging parties.   

The U.S. Department of Health and Human Services’ (HHS) Office of Research Integrity (ORI) published its long-anticipated Guidance on Generative Artificial Intelligence in August. The guidance explains how generative AI (GenAI) use is evaluated under the revised research misconduct regulations (42 CFR Part 93), which took effect January 1, 2025, and became applicable to new allegations on January 1, 2026. The new guidance builds on prior guidance documents regarding the definitions of fabrication, falsification, and plagiarism, as well as revised evidentiary standards. As of April 30, 2026, institutions were required to have compliant policies on file with ORI as part of their annual report covering 2025. 

Part Two of a Two-Part Client Alert Series. This Alert builds on the discussion in Part One, which surveyed Bear Creek (2017), Copper Mesa (2016), South American Silver (2018), Eco Oro (2021), and Lupaka (2025).

New York Attorney General Letitia James has issued an industry-wide alert encouraging workers with knowledge of unsafe or illegal conduct at artificial intelligence (AI) companies to file confidential whistleblower complaints through the Office of the Attorney General’s (OAG) secure portal. This development signals a significant escalation in regulatory scrutiny of the AI sector and should be carefully considered by any company developing or deploying AI technology that has a nexus to New York.

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. 

This Alert, the first in a two-part series, surveys the legal landscape at the intersection of two issues that increasingly shape the outcome of mining and natural resources disputes regarding the protections available to foreign investors under investment treaties, as enforced through Investor-State Dispute Settlement (ISDS). The first is the prior consultation obligation imposed on States under the Indigenous and Tribal Peoples Convention, 1989 (No. 169), adopted by the International Labour Organization (ILO 169). The second is social license, the practical acceptance of a project by surrounding communities, which is distinct from but related to the formal State consultation duty. This Alert examines these issues across five foundational ISDS decisions:

On September 2, 2026, the National Archives and Records Administration (NARA), through its Information Security Oversight Office (ISOO), released two new Notices on the topic of Controlled Unclassified Information (CUI): ISOO Notices 2026-07 and 2026-08. 

This news bulletin is provided by the International Trade Group of Crowell & Moring. If you have questions or need assistance on trade law matters, please contact Anand Sithian or Simeon Yerokun or any member of the International Trade Group.

The U.S. Food & Drug Administration (FDA) is seeking feedback on a regulatory framework that could be used to evaluate generative artificial intelligence (GenAI)-enabled medical devices. Such devices could create new types of risks because their outputs can vary and evolve, unlike more traditional software-enabled devices. An August 18, 2026, discussion paper (“Considerations for the regulation of GenAI-enabled medical devices”) discusses potential regulatory considerations for GenAI-enabled medical devices.